Showing results (851-860 of 2,510) with videos related to
Sort By:
Pageof 251
Journal of the International AIDS Society|November 15, 2014
Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adultsEduardo Arathoon, Asad Bhorat, Rodica Silaghi, et al.Journal of the International AIDS Society|November 15, 2014
Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levelsSameshnee Kelly Pillay, Urisha Singh, Avashna Singh, et al.Journal of the International AIDS Society|November 15, 2014
Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trialsJose Arribas, Pierre-Marie Girard, Nicholas Paton, et al.Journal of the International AIDS Society|November 15, 2014
Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114Isabel A Pérez-Hernández, Rosario Palacios, Marisa Mayorga, et al.Journal of the International AIDS Society|November 15, 2014
Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patientsJose Luis Casado, Sara Bañón, Ana Moreno, et al.Journal of the International AIDS Society|November 15, 2014
Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER StudyJoaquín Portilla, Piedad Arazo, Josefa Crusells, et al.Journal of the International AIDS Society|November 15, 2014
Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysisJose Arribas, Giuliano Rizzardini, Keikawus Arasteh, et al.Journal of the International AIDS Society|November 15, 2014
Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppressionJosep M Llibre, Alessandro Cozzi-Lepri, Jorge Antonio Valencia La Rosa, et al.Journal of the International AIDS Society|November 15, 2014
Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: 96 weeks post VERITAS studyBenoit Trottier, Daniele Longpré, Harold Dion, et al.Journal of the International AIDS Society|November 15, 2014
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA studyRoberta Gagliardini, Barbara Rossetti, Claudia Bianco, et al.Pageof 251